16 related articles for article (PubMed ID: 9268187)
1. Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects.
Mousa SA; Zhang F; Aljada A; Chaturvedi S; Takieddin M; Zhang H; Chi L; Castelli MC; Friedman K; Goldberg MM; Linhardt RJ
J Clin Pharmacol; 2007 Dec; 47(12):1508-20. PubMed ID: 18048572
[TBL] [Abstract][Full Text] [Related]
2. Correction: Group-by-Treatment Interaction Effects in Comparative Bioavailability Studies.
Schütz H; Burger DA; Cobo E; Dubins DD; Farkás T; Labes D; Lang B; Ocaña J; Ring A; Shitova A; Stus V; Tomashevskiy M
AAPS J; 2024 May; 26(3):58. PubMed ID: 38710975
[No Abstract] [Full Text] [Related]
3. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
Alban S; Welzel D; Hemker HC
Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
[TBL] [Abstract][Full Text] [Related]
5. The dose proportionality of the pharmacokinetics of ardeparin, a low molecular weight heparin, in healthy volunteers.
Troy S; Fruncillo R; Ozawa T; Mammen E; Holloway S; Chiang S
J Clin Pharmacol; 1995 Dec; 35(12):1194-9. PubMed ID: 8750371
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
7. Monitoring the anticoagulant effects of a low molecular weight heparin preparation. Correlation of assays in orthopedic surgery patients receiving ardeparin sodium for prophylaxis of deep venous thrombosis.
Kessler CM; Esparraguera IM; Jacobs HM; Druy E; Fortune WP; Holloway DS; Giordano J; Davidson BL
Am J Clin Pathol; 1995 May; 103(5):642-8. PubMed ID: 7741113
[TBL] [Abstract][Full Text] [Related]
8. Absolute and comparative subcutaneous bioavailability of ardeparin sodium, a low molecular weight heparin.
Troy S; Fruncillo R; Ozawa T; Mammen E; Holloway S; Chiang S
Thromb Haemost; 1997 Aug; 78(2):871-5. PubMed ID: 9268187
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
